enGene (NASDAQ:ENGN) Given “Buy” Rating at HC Wainwright

enGene (NASDAQ:ENGN)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $4.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 112.20% from the stock’s previous close.

A number of other analysts have also issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of enGene in a report on Wednesday, August 12th. Morgan Stanley lowered enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 price target on the stock. in a research report on Thursday, June 18th. UBS Group dropped their price objective on shares of enGene from $9.00 to $2.00 and set a “neutral” rating on the stock in a research note on Thursday, May 14th. Finally, Wall Street Zen upgraded shares of enGene from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Four equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, enGene currently has a consensus rating of “Hold” and a consensus target price of $11.05.

enGene Stock Up 3.6%

Shares of ENGN traded up $0.07 during midday trading on Tuesday, hitting $1.89. The company had a trading volume of 694,833 shares, compared to its average volume of 1,005,779. The company’s 50 day moving average price is $1.82 and its 200 day moving average price is $4.11. The stock has a market cap of $126.28 million, a price-to-earnings ratio of -0.87 and a beta of -0.28. The company has a quick ratio of 12.57, a current ratio of 12.57 and a debt-to-equity ratio of 0.10. enGene has a 52 week low of $1.40 and a 52 week high of $12.25.

enGene (NASDAQ:ENGN) last released its earnings results on Tuesday, September 8th. The company reported ($0.47) earnings per share for the quarter, hitting the consensus estimate of ($0.47). On average, equities research analysts predict that enGene will post -1.84 EPS for the current year.

Institutional Trading of enGene

Several large investors have recently made changes to their positions in the business. Cresset Asset Management LLC bought a new position in shares of enGene during the 2nd quarter valued at about $36,000. Raymond James Financial Inc. grew its holdings in shares of enGene by 383.6% during the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after purchasing an additional 7,932 shares in the last quarter. Paloma Partners Management Co bought a new position in shares of enGene in the second quarter worth $38,000. Jump Financial LLC bought a new position in shares of enGene in the fourth quarter worth $121,000. Finally, Millennium Management LLC raised its stake in enGene by 57.3% in the third quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock valued at $140,000 after purchasing an additional 7,472 shares in the last quarter. Institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.